Blood-brain barrier imaging and therapeutic potentials

Topics in Magnetic Resonance Imaging

Volumn 17, Issue 2, 2006, Pages 107-116

  Rebeles, Fidel ^a   Fink, James ^a   Anzai, Yoshimi ^a   Maravilla, Kenneth R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Blood brain barrier; Imaging; Permeability

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; BRADYKININ; CARBOPLATIN; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOBRADIMIL; MANNITOL; METHOTREXATE; METHYLPREDNISOLONE; MEVINOLIN;

ANATOMY; ANGIOGENESIS; BIOCHEMISTRY; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; BRAIN LYMPHOMA; BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE MARKER; DRUG DELIVERY SYSTEM; EVALUATION; HUMAN; MEASUREMENT; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PERMEABILITY BARRIER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SAFETY; TREATMENT RESPONSE; VALIDATION STUDY;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; PERMEABILITY;

EID: 33846006196     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e31802f5df9     Document Type: Review

References (56)

1. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083-1099.
2. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1-13.
3. Partridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem. 1985;44:1771-1778.
4. Kemper EM, Boogerd W, Thuis I, et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumors? Cancer Treat Rev. 2004;30:415-423.
5. Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100:323-331.
6. Papadopoulos MC, Saadoun S, Woodrow CJ, et al. Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol Appl Neurobiol. 2001;27:384-395.
7. Neuhaus J, Risau W, Wolburg H. Induction of blood-brain barrier characteristics in bovine brain endothelial cells by rat astroglial cells in transfilter coculture. Ann N Y Acad Sci. 1991;633:578-580.
8. Fischer S, Clauss M, Wiesnet M, et al. Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am J Physiol. 1999;276:C812-C820.
9. Bolton SJ, Anthony DC, Perry VH. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience. 1998;86:1245-1257.
10. Hai J, Li ST, Lin Q, et al. Vascular endothelial growth factor expression and angiogenesis induced by chronic cerebral hypoperfusion in rat brain. Neurosurgery. 2003;53:963-970.
11. Lou J, Chofflon M, Juillard C, et al. Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity. Neuroreport. 1997;8:629-633.
12. Croll SD, Ransohoff RM, Cai N, et al. VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp Neurol. 2004;187:388-402.
13. Nag S, Eskandarian MR, Davis J, et al. Differential expression of vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury. J Neuropathol Exp Neurol. 2002;61:778-788.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
15. Dunn IF, Heese O, Black PM. Growth factors in gliomas angiogenesis: FGFs, PDGFs, EGF, and TGFs. J Neuro-Oncol. 2000;50:121-137.
16. Machein MR, Plate KH. VEGF in brain tumors. J Neuro-Oncol. 2000;50:109-120.
17. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neuro-Oncol. 2000;50:99-109.
18. Long DM. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg. 1970;32:127-144.
19. Saadoun S, Papadopoulos MC, Davies DC, et al. Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry. 2002;72:262-265.
20. Tofts PS, Brix G, Buckley D, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J MRI. 1999;10:223-232.
21. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol. 2003;76:S60-S80.
22. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17:357-367.
23. Tofts PS, Kermode AG. Blood brain barrier permeability in multiple sclerosis using labelled DTPA with PET, CT and MRI. J Neurol Neurosurg Psychiatry. 1989;52:1019-1020.
24. Yang S, Law M, Zagzag D, et al. Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol. 2003;24:1443-1559.
25. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21:891-899.
26. Cha S, Yang L, Johnson G, et al. Comparison of microvascular permeability measurements, Ktrans, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol. 2006;27:409-417.
27. Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med. 2002;47:601-606.
28. Law M, Yang S, Babb J, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with gliomas grade. AJNR Am J Neuroradiol. 2004;25:746-755.
29. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
30. Schmiedl UP, Kenney J, Maravilla KR. Kinetics of pathologic blood-brain-barrier permeability in an astrocytic glioma using contrast-enhanced MR. AJNR Am J Neuroradiol. 1992;13:5-14.
31. Johnson G, Wetzel S, Cha S. Simultaneous Measurement of Blood Volume and Vascular Transfer Constant by First Pass Pharmacokinetic Modeling. Proceedings of the International Society for Magnetic Resonance in Medicine. Berkeley, CA: International Society for Magnetic Resonance in Medicine; 2002.
32. Provenzale JM, Wang GR, Brenner T, et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol. 2002;178:711-716.
33. Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging. 2002;15:233-240.
34. Provenzale JM, Mukundan S, Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol. 2005;185:763-767.
35. Uematsu H, Maeda M, Sadato N, et al. Vascular permeability: quantitative measurement with double-echo dynamic MR imaging-theory and clinical application. Radiology. 2000;214:912-917.
36. Liebsch R, Kornhuber ME, Dietl D, et al. Blood-CSF barrier integrity in multiple sclerosis. Acta Neurol Scand. 1996;94:404-410.
37. Su JJ, Osoegawa M, Matsuoka T, et al. Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci. 2006;243:21-30.
38. Barkhof F, Hommes OR, Scheltens P, et al. Quantitative MRI changes ingadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991;41:1219-1222.
39. Floris S, Blezer EL, Schreibelt G, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain. 2004;127(pt 3):616-627.
40. Ifergan I, Wosik K, Cayrol R, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006;60:45-55.
41. Larsson H, Frederiksen JL, Jensen M, et al. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med. 1990;16:117-131.
42. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR Imaging. J MRI. 1997;7:91-101.
43. Veltkamp R, Siebing DA, Sun L, et al. Hyperbaric oxygen reduces blood-brain barrier damage and edema after transient focal cerebral ischemia. Stroke. 2005;36:1679-1683.
44. Kassner A, Roberts T, Taylor K, et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol. 2005;26:2213-2217.
45. Kimura R, Nakase H, Tamaki R, et al. Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction. Stroke. 2005;36:1259-1263.
46. Neuwelt EA, Frenkel EP, Rapoport S, et al. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery. 1980;7:482-490.
47. Zunkeler B, Carson RE, Olson J, et al. Hyperosmolar blood-brain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82. J Neurosurg. 1996;84:494-502.
48. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637-647.
49. Fortin D, Desjardins A, Benko A, et al. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer. 2005;103:2606-2615.
50. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 1990;27:573-574.
51. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46:51-60.
52. Roman-Goldstein S, Mitchell P, Crossen JR, et al. MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. AJNR Am J Neuroradiol. 1995;16:543-553.
53. Prados MD, Schold SC JR SC, Fine HA, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant gliomas. Neuro-oncology. 2003;5:96-103.
54. Remsen LG, McCormick CI, Roman-Goldstein S, et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol. 1996;17:411-418.
55. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993;261:212-215.
56. Ostegaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg. 1999;90:300-305.